stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
25.52
0.51
−1.96%
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) Book value per share
Caris Life Sciences,�Inc.'s book value per share at the end of fiscal 2025 was 3.5×, compared with −70.4× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 0.0×. Caris Life Sciences,�Inc. ranks 477th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 3.5× | — |
| FY2024 | −70.4× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 2.1× | (0.41%) |
| Mar 2026 | 2.1× | 2.68% |
| Dec 2025 | 2.0× | 20.63% |
| 7 more quarters | Free account |
Book value per share against peers
| Company | Book value per share |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 48.5× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 21.4× |
| PTGX Protagonist Therapeutics, Inc. compare | 12.8× |
| SYRE Spyre Therapeutics, Inc. compare | 11.9× |
| TWST Twist Bioscience Corporation compare | 7.1× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| CYTK Cytokinetics, Incorporated compare | 0.0× |
| CAI Caris Life Sciences,�Inc. | 0.0× |
| IBRX ImmunityBio, Inc. compare | −1.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on CAI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- The full statement